Share on StockTwits

Marrone Bio Innovations (NASDAQ:MBII) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday. They currently have a $6.60 price target on the stock. Zacks‘s target price suggests a potential upside of 25.71% from the company’s current price.

Shares of Marrone Bio Innovations (NASDAQ:MBII) remained flat at $5.25 during during mid-day trading trading on Wednesday. 111,895 shares of the company’s stock traded hands. Marrone Bio Innovations has a one year low of $5.17 and a one year high of $20.00. The stock has a 50-day moving average of $9.80 and a 200-day moving average of $12.08. The company’s market cap is $109.1 million.

Marrone Bio Innovations (NASDAQ:MBII) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.47) by $0.03. On average, analysts predict that Marrone Bio Innovations will post $-1.77 earnings per share for the current fiscal year.

A number of other firms have also recently commented on MBII. Analysts at Robert W. Baird downgraded shares of Marrone Bio Innovations from an “outperform” rating to a “neutral” rating in a research note on Friday, August 8th. They now have a $12.00 price target on the stock, down previously from $15.00. Separately, analysts at Piper Jaffray downgraded shares of Marrone Bio Innovations from an “overweight” rating to a “neutral” rating in a research note on Friday, August 8th. They now have a $11.00 price target on the stock, down previously from $19.00. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $14.43.

Marrone Bio Innovations, Inc is a provider of bio-based pest management and plant health products. Bio-based products are consists of naturally occurring microorganisms, such as bacteria and fungi, and plant extracts.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.